Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3319483
Max Phase: Preclinical
Molecular Formula: C37H44N4O5
Molecular Weight: 624.78
Molecule Type: Small molecule
Associated Items:
ID: ALA3319483
Max Phase: Preclinical
Molecular Formula: C37H44N4O5
Molecular Weight: 624.78
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1=C(C(=O)N[C@H](C)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CC2CCCCC2)C(=O)[C@@]2(C)CO2)Cc2ccccc21
Standard InChI: InChI=1S/C37H44N4O5/c1-22-27-14-8-7-13-25(27)18-29(22)35(44)39-23(2)34(43)41-32(19-26-20-38-30-16-10-9-15-28(26)30)36(45)40-31(33(42)37(3)21-46-37)17-24-11-5-4-6-12-24/h7-10,13-16,20,23-24,31-32,38H,4-6,11-12,17-19,21H2,1-3H3,(H,39,44)(H,40,45)(H,41,43)/t23-,31+,32+,37-/m1/s1
Standard InChI Key: HCSMZVMWZMSHSC-LZNHGOJSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 624.78 | Molecular Weight (Monoisotopic): 624.3312 | AlogP: 4.54 | #Rotatable Bonds: 12 |
Polar Surface Area: 132.69 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.24 | CX Basic pKa: | CX LogP: 5.33 | CX LogD: 5.33 |
Aromatic Rings: 3 | Heavy Atoms: 46 | QED Weighted: 0.22 | Np Likeness Score: 0.26 |
1. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS.. (2014) Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes., 57 (14): [PMID:25006746] [10.1021/jm500716s] |
2. Xin BT, de Bruin G, Huber EM, Besse A, Florea BI, Filippov DV, van der Marel GA, Kisselev AF, van der Stelt M, Driessen C, Groll M, Overkleeft HS.. (2016) Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes., 59 (15): [PMID:27438186] [10.1021/acs.jmedchem.6b00705] |
Source(1):